Genzyme Temporarily Interrupts Production at Allston Plant
Genzyme Corporation announced that it has detected a virus that impairs cell growth in one of six bioreactors at its Allston Landing manufacturing facility. The company has decided to temporarily interrupt bulk production at the plant to sanitize the facility. Genzyme is collaborating with regulatory agencies as it works to resume production. The company expects the plant to be fully operational by the end of July.
The virus strain, Vesivirus 2117, has not been shown to cause human infection. It is known to interfere with the growth of CHO cells used to produce biologic drugs and was likely introduced through a nutrient used in the manufacturing process. Genzyme has now confirmed that this virus was the cause of declines in cell productivity at its Allston and Geel facilities in two previous instances in 2008, which were subsequently fully addressed. The company was able to detect the virus in this case using a highly specific assay it developed after standard tests were unable to identify the cause of the previous productivity declines. Genzyme is adding steps to increase the robustness of its raw materials screening and viral removal processes.
Current inventories for Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) are not sufficient to meet projected global demand. The timing and extent of the Cerezyme supply constraint is being clarified and will be communicated as soon as possible. The company expects Fabrazyme supply constraints to occur for a limited period beginning in September. The company will work with physicians, patients and regulators to minimize the impact of this constraint.
Genzyme identified the virus at the Allston plant over the weekend. On Monday morning, the company submitted information to the FDA and EMEA on its findings. The company held a conference call with the FDA on Monday afternoon. With regulatory input, Genzyme is finalizing its action plan and assessing the business impact of this situation. The company will provide updated financial guidance as soon as possible.
Other news from the department business & finance
These products might interest you
Biostat STR by Sartorius
Biostat STR Generation 3 Bioreactors
Engineered for Ultimate Upstream Performance
Ambr® 250 Modular by Sartorius
Mini bioreactors for cell and gene therapies with high scalability
Maximise your process development with reliable single-use vessels
Ambr® 250 HT Consumables by Sartorius
Efficient bioprocesses with single-use bioreactors
Minimise cleaning effort and maximise flexibility for cell and microbial cultures
Brooks Instrument SLA Biotech-Serie by Brooks Instrument
Control bioprocesses efficiently and precisely with flow controllers for biotechnology applications
The SLA Biotech series has been developed specifically for the requirements in bioprocesses
Flexcell Systems by Dunn
Flexcell Cell Stretching Bioreactors for Life Science Research
Used in over 1300 laboratories worldwide, and cited in over 4000 research publications
SLAMf Biotech-Serie Massendurchflussregler by Brooks Instrument
SLAMf Mass Flow Controllers Designed Specifically for Biotech (IP66 / NEMA 4X)
Special equipment for biotech process plants, suitable for splash water and high-pressure cleaning
